TREA

90803650 - COMPLEGENT

Follow

Information

  • Trademark
  • 90803650
  • Serial Number
    90803650
  • Registration Number
    6915728
  • Filing Date
    June 30, 2021
    3 years ago
  • Registration Date
    December 06, 2022
    2 years ago
  • Transaction Date
    August 08, 2023
    a year ago
  • Status Date
    December 06, 2022
    2 years ago
  • Published for Opposition Date
    September 20, 2022
    2 years ago
  • Location Date
    July 06, 2023
    a year ago
  • Status Code
    700
  • Current Location
    TMEG LAW OFFICE 104
    Employee Name
    MESSICK, TABITHA LEE
  • Attorney Docket Number
    0098505-020
    Attorney Name
    Bassam N. Ibrahim
    Law Office Assigned Location Code
    L40
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
COMPLEGENT
Case File Statements
  • GS0401: Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; custom manufacturing, namely, contract refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of host cells; technical consultation in the field of custom manufacturing in the field of host cells; providing technical information in the field of contract manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; technical consultation in the field of manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals
  • B00001: In the statement, " 11/28/2018 and 11/20/2028 " should be deleted, and 11/28/2008 and 11/28/2028 should be inserted. In the statement, 06/12/2018 is inserted.
  • GS0421: Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells
Case File Event Statements
  • 8/8/2023 - a year ago
    26 - NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED Type: NURC
  • 7/6/2023 - a year ago
    25 - CORRECTION UNDER SECTION 7 ¿ PROCESSED Type: COC.
  • 7/3/2023 - a year ago
    24 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 12/21/2022 - 2 years ago
    23 - TEAS SECTION 7 REQUEST RECEIVED Type: ES7R
  • 12/6/2022 - 2 years ago
    22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 12/6/2022 - 2 years ago
    21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/14/2022 - 2 years ago
    20 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA
  • 10/20/2022 - 2 years ago
    19 - ASSIGNED TO PETITION STAFF Type: APET
  • 10/5/2022 - 2 years ago
    18 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA
  • 9/20/2022 - 2 years ago
    17 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/20/2022 - 2 years ago
    16 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/31/2022 - 2 years ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/13/2022 - 2 years ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/27/2022 - 2 years ago
    13 - PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Type: AMPX
  • 7/27/2022 - 2 years ago
    12 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 7/26/2022 - 2 years ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/25/2022 - 2 years ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/25/2022 - 2 years ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/16/2022 - 3 years ago
    8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/16/2022 - 3 years ago
    7 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/16/2022 - 3 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/9/2022 - 3 years ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/21/2021 - 3 years ago
    4 - TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED Type: TAEA
  • 7/21/2021 - 3 years ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 9/12/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/3/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP